Redeye’s optimistic view on the BONESUPPORT case remains following today’s report despite a slowdown in sales growth. We expect orthopaedic surgeries to accelerate significantly during H2, which, together with several exciting near-term catalysts, should fuel both its share price and revenue growth.
LÄS MER
